Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Morgan Stanley Downgrades Y-mAbs Therapeutics to Underweight

Morgan Stanley Downgrades Y-mAbs Therapeutics to Underweight

Morgan Stanley analyst Michael Ulz downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Equal-Weight to Underweight.

byBenzinga Newsdesk

January 27, 2023

1 minute read

Morgan Stanley analyst Michael Ulz downgrades Y-mAbs Therapeutics (NASDAQ:YMAB) from Equal-Weight to Underweight.

Analyst Ratings

Mizuho Maintains Neutral Rating for Sealed Air: Here’s What You Need To Know

By Benzinga Insights

May 31, 1:00 PM

Mizuho has decided to maintain its Neutral rating of Sealed Air (NYSE:SEE) and lower its price target from…

SEE

News

Why DoorDash Shares Are Trading Higher

By Henry Khederian

March 7, 3:55 PM

DoorDash Inc (NYSE: DASH) shares are trading higher by 3.72% to $58.02 Tuesday afternoon after New York City decreased the proposed minimum delivery worker pay target for 2025.

DASH

News

Clene To Report HEALEY ALS Platform Trial Topline Results On Monday, October 3

By Michael Horton

September 30, 4:13 PM

Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of

CLNN